Pipeline

Clinical Trial Enrollment Contact

Building a Broad Pipeline of
Indications

Mechanism of Action: Leronlimab as a CCR5 antagonist

Program	Indication	Pre-clinical	Phase 1	Phase 2	Phase 3
HIV
	Combination Therapy ¹	Pre-clinical Phase complete	Phase 1 Phase complete	Phase 2 Phase complete	Phase 3 Phase in progress
	Monotherapy ²	Pre-clinical Phase complete	Phase 1 Phase complete	Phase 2 Phase complete	Phase 3 Phase in progress
Immunology
	GvHD ³	Pre-clinical Phase complete	Phase 1 Phase complete	Phase 2 Phase in progress	Phase 3 Phase not started
	NASH	Pre-clinical Phase in progress	Phase 1 Phase not started	Phase 2 Phase not started	Phase 3 Phase not started
Cancer
	Triple-Negative Breast ⁴	Pre-clinical Phase complete	Phase 1 Phase complete	Phase 2 Phase in progress	Phase 3 Phase not started
	Colon	Pre-clinical Phase in progress	Phase 1 Phase not started	Phase 2 Phase not started	Phase 3 Phase not started
	Prostate	Pre-clinical Phase in progress	Phase 1 Phase not started	Phase 2 Phase not started	Phase 3 Phase not started
	Pancreatic	Pre-clinical Phase in progress	Phase 1 Phase not started	Phase 2 Phase not started	Phase 3 Phase not started
	Melanoma	Pre-clinical Phase in progress	Phase 1 Phase not started	Phase 2 Phase not started	Phase 3 Phase not started
	Liver	Pre-clinical Phase in progress	Phase 1 Phase not started	Phase 2 Phase not started	Phase 3 Phase not started
	Lung	Pre-clinical Phase in progress	Phase 1 Phase not started	Phase 2 Phase not started	Phase 3 Phase not started
	Stomach	Pre-clinical Phase in progress	Phase 1 Phase not started	Phase 2 Phase not started	Phase 3 Phase not started

BLA filing underway, 1/3 completed
Protocol for pivotal Phase 3 trial filed
Trial underway with Orphan Drug Designation
Trial underway with Fast Track Designation

Licensing Opportunities

Mechanism of Action: Proprietary gene sequencing, A.I.

Program	Indication	510(k)
Prognostic
Prognostic	Prostate Cancer ¹	510(k) Phase in progress

In discussions and seeking 510(k)

Leronlimab for HIV Treatment

Our lead product, Leronlimab (PRO 140), is the world’s first self-injectable, subcutaneous injection for HIV and has many advantages over the current standard of care, HAART, including no serious side effects, enhanced compliance, and longer half-life.

Leronlimab for Cancer Metastasis

Recent research demonstrated the importance of CCR5 in cancer indications and indicates that Leronlimab (PRO 140) is a potential inhibitor of the CCR5 receptor.

Mitigating Acute GVHD with Leronlimab

Graft-versus-host disease (GVHD) is a serious complication that limits the use of Bone Marrow Stem Cell (BMSC) transplantation in patients with blood cancers. Our current clinical trial studies Leronlimab for the prevention of GVHD in patients (RIC) undergoing BMSC transplantation.

PCa Test for Accurate Prostate Cancer Diagnosis

Our PCa Test is an unbiased and valuable tool to provide guidance to assist the physician and prostate cancer patient to make a more informed decision regarding a potentially life-altering surgery based on their true risk profile.

Get In Touch

For more information on Leronlimab, our science, or our new developments, please reach out to us using the link provided.

Ask a Question